Abstract
Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.
© 2011 Blackwell Publishing Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acute Coronary Syndrome / blood
-
Acute Coronary Syndrome / mortality
-
Acute Coronary Syndrome / therapy*
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Angioplasty, Balloon, Coronary / mortality
-
Drug Interactions
-
Drug Resistance
-
Evidence-Based Medicine
-
Hemorrhage / chemically induced
-
Humans
-
Myocardial Infarction / etiology
-
Myocardial Infarction / mortality
-
Myocardial Infarction / prevention & control
-
Piperazines / adverse effects
-
Piperazines / pharmacokinetics
-
Piperazines / therapeutic use*
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prasugrel Hydrochloride
-
Purinergic P2Y Receptor Antagonists / adverse effects
-
Purinergic P2Y Receptor Antagonists / pharmacokinetics
-
Purinergic P2Y Receptor Antagonists / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Risk Factors
-
Thiophenes / adverse effects
-
Thiophenes / pharmacokinetics
-
Thiophenes / therapeutic use*
-
Thrombosis / etiology
-
Thrombosis / mortality
-
Thrombosis / prevention & control
-
Time Factors
-
Treatment Outcome
Substances
-
Piperazines
-
Platelet Aggregation Inhibitors
-
Purinergic P2Y Receptor Antagonists
-
Thiophenes
-
Prasugrel Hydrochloride